15:55:08 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-12 Bokslutskommuniké 2024
2024-11-06 Kvartalsrapport 2024-Q3
2024-08-07 Kvartalsrapport 2024-Q2
2024-05-22 Ordinarie utdelning XSPRAY 0.00 SEK
2024-05-21 Årsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-02-14 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-02 Kvartalsrapport 2023-Q2
2023-05-25 Extra Bolagsstämma 2023
2023-05-16 Årsstämma 2023
2023-05-05 Ordinarie utdelning XSPRAY 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-15 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-05 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning XSPRAY 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-08-06 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning XSPRAY 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-07-31 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning XSPRAY 0.00 SEK
2020-05-14 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-03-26 Extra Bolagsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-23 Årsstämma 2019
2019-05-17 Ordinarie utdelning XSPRAY 0.00 SEK
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-11-28 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-16 Ordinarie utdelning XSPRAY 0.00 SEK
2018-05-14 Årsstämma 2018
2018-05-14 Kvartalsrapport 2018-Q1
2018-02-20 Extra Bolagsstämma 2017
2018-02-19 Bokslutskommuniké 2017
2017-11-22 Kvartalsrapport 2017-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Xspray Pharma är ett läkemedelsbolag med målet att förbättra livskvaliteten för cancerpatienter. Bolaget har flera produktkandidater i klinisk utvecklingsfas och planerar att lansera sin första produkt på den amerikanska marknaden under september 2024. Baserat på en patenterad teknologi för amorf formulering av läkemedel utvecklar bolaget produktkandidater med relevanta medicinska fördelar som ska kunna marknadsföras som förbättrade versioner av etablerade läkemedel för behandling av cancer (proteinkinashämmare, PKI:er).
2020-05-14 08:30:00

“This year is an important year for Xspray. I expect that the amorphous material provided by our unique production facility will provide positive clinical data, which is a prerequisite for us to apply for market approval for HyNap-Dasa in the U.S. This means that we together with a partner who either buys or licenses the HyNap-Dasa product, will gain access to a multibillion market.” Per Andersson, CEO Xspray Pharma AB (publ)

Significant events during January – March 2020

  • In February, stability studies for the final HyNap-Dasa tablets were initiated and will be a part of the company’s ANDA application.
  • In February, four new patents for the pharmaceutical composition of the company’s primary product candidate, HyNap-Dasa, were granted in the US.
  • In March, Xspray’s production partner, Nerpharma, received approval from Italian Medicines Agency (AIFA) for the full-scale production facility
  • In March, Nasdaq Stockholm's listing committee approved Xspray's application to be listed on Nasdaq Stockholm main market. The first trading day on Nasdaq Stockholm was March 27.

Significant events after the end of the reporting period

  • In mid-April, Xspray announced that the start of pivotal clinical bioequivalence studies with HyNap-Dasa will be delayed by two to three months due to the Covid-19 pandemic.

January – March 2020, Group

  • Net sales amounted to SEK 0 thousand (0)
  • Earnings before tax amounted to SEK -10,532 thousand ( -7,753)
  • Earnings per share before dilution amounted to SEK -0.63 (-0.51)
  • Cash flow from operating activities amounted to SEK -13,490 thousand (-12,926)
  • Cash flow from investing activities amounted to SEK -23,918 thousand (-15,473)

January – March 2020, Parent Company

  • Net sales amounted to SEK 0 thousand (0)
  • Earnings before tax amounted to SEK -10,513 thousand (-7,792)
  • Earnings per share before dilution amounted to SEK -0.63 (-0.52)
  • Cash flow from operating activities amounted to SEK -13,245 thousand (-12,943)

Amounts in brackets refer to the corresponding period for the previous year

The report is available on the company’s website: http://xspraypharma.com/en/investors/financial-reports/